MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: We further show that the combined inhibition of Bcr-Abl, CK2 and MEK/ERK1/2 may afford a novel strategy to counteract CML imatinib-resistance by means of synergistic effects.